Biotech

Inside the discoveries, personalities, and deals driving drug development. Sign up for the Readout newsletter here.

Westin St. Francis hotel
Adam's Take

On the cusp of the ‘JPM,’ here’s a cheat sheet for what to watch in biotech in 2019

By Adam Feuerstein

Meghana Limericks 2018
Biotech

2018 in limericks: The highs and lows from the life sciences

By Meghana Keshavan

Comeback illo
Biotech

2018’s comeback kid: Endocyte goes from nosedive to Novartis’ latest acquisition

By Kate Sheridan

3 to Watch: China
Biotech

3 China biotech stories to watch in 2019

By Rebecca Robbins

3 to Watch: Biotech
Biotech

3 trends in biotech to watch in 2019

By Damian Garde

Biotech graveyard
Biotech

Crash and burn: Why three biotechs failed in 2018

By Kate Sheridan

Alexion Pharmaceuticals Inc
Biotech

Alexion wins approval for rare disease drug, aims to switch patients from blockbuster Soliris

By Adam Feuerstein

Biotech

After Sarepta, going after the genetic causes of epilepsies at Stoke

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Stealth bomber
Biotech

New details emerge about a stealth startup backed by Flagship Pioneering

By Kate Sheridan

The Readout LOUD

LISTEN: Watson’s latest stumble, a glimpse into the crystal ball, and revisiting Sarepta

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Biotech

Relay Therapeutics raises $400 million in venture capital funding

By Jonathan Saltzman — Boston Globe

GENERAL ELECTRIC PLANT - Pittsfield
Biotech

Massachusetts is trying to make the Berkshires a biotech hub. Can it succeed where so many other cities have failed?

By Kate Sheridan

Peanuts
Biotech

DBV Technologies pulls peanut allergy treatment from FDA review

By Adam Feuerstein

Good/Bad CEO 2017
Adam's Take

Leiden victorious in best biopharma CEO tally; Alles tops worst list

By Adam Feuerstein

Human Milk Bank
Health

Scientists turn to breast milk, and Mother Nature, to develop new therapeutics

By Meghana Keshavan

Lifesaver ocean
Biotech

Can precision medicine rescue a multibillion-dollar pharma debacle?

By Damian Garde

STAT SPOTLIGHT
Biotech

Startup Spotlight: PanTher’s drug-delivery patch aims to knock down the ‘wall’ of pancreatic cancer

By Kate Sheridan

The Readout LOUD

LISTEN: Gilead’s new boss, the year that was, and the thing about DNA tests

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Medical costs
Pharma

A drug that was once inexpensive gets a new price tag: $375,000

By Meghana Keshavan

Broken pills concept
Biotech

What to watch in biotech at the JPM Healthcare Conference and beyond in 2019

By Adam Feuerstein

Worst Biotech CEOs 2017
Adam's Take

And now, your nominees for worst biopharma CEO of 2018. Let the voting begin!

By Adam Feuerstein

Best Biotech CEOs 2017
Adam's Take

Introducing the nominees for best biopharma CEO of 2018. Vote for your favorite!

By Adam Feuerstein

Cambridgeport
Exclusive

New documents shed light on secretive ElevateBio, next step for former Alexion execs

By Kate Sheridan

Adam's Take

Why Gilead’s new CEO is a solid choice to help the biotech grow again

By Adam Feuerstein

Biotech

Moderna’s record-setting IPO dives in its debut

By Damian Garde

The Readout LOUD

LISTEN: Using the word ‘cure,’ an FDA loophole, & making biotech history

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Donald Trump & Xi Jinping
Politics

The Trump administration called this biotech VC firm a suspicious agent of China. It’s run by U.S. citizens

By Rebecca Robbins

Steve Burrill
Biotech

Legendary biotech VC Steven Burrill sentenced to 2.5 years for fraud

By Damian Garde

Biotech

Four big questions ahead of Moderna’s public debut — biotech’s biggest ever

By Damian Garde

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy